![]() ![]() The phase III study included 1,128 people with locally advanced rectal cancer that had spread to nearby tissue or lymph nodes, meaning they were eligible to receive chemotherapy and radiation therapy before surgery. Often, side effects of cancer treatment may be bearable in the short term but have a significant effect on a patient’s quality of life that can last longer than the treatments. The toxicity and tolerability of cancer therapies are important for many reasons, including that patients who experience bad side effects may not be able to finish their full course of treatment, reducing their chance of successful treatment. This consortium seeks to expand upon the use and reach of the PRO-CTCAE and other PRO instruments that can inform symptomatic toxicities and their impacts, as well as develop more methods to analyze and report. “The findings of this study allow us to do just that, showing we can omit radiation therapy for some patients, improving quality of life without compromising efficacy.” “As we develop new therapies, we are also exploring where we can eliminate toxic therapies for our patients’ wellbeing,” she said. Kunz, M.D., an ASCO expert, in a press release. The findings are “practice changing,” said Pamela L. Findings were simultaneously published in the New England Journal of Medicine (efficacy) and the Journal of Clinical Oncology (PROs). This is important because omitting radiation therapy can reduce both short- and long-term side effects that impact quality of life-including fertility problems, diarrhea, and bowel and bladder problems-and the results show this can be done while having similar outcomes in disease-free and overall survival. In a plenary session at the meeting, findings from the NCI-supported PROSPECT clinical trial were presented showing that patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation therapy before surgery. Omitting Radiation Therapy Possible for Some Patients with Rectal Cancer The study results, which both incorporated data from patient-reported outcomes (PROs), have the potential to help reduce toxic side effects and improve quality of life for people with cancer. Results from two NCI-supported studies relating to symptom management were among the significant findings presented at the June 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO). Community Oncology and Prevention Trials.US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet).Translational Liver Cancer (TLC) Consortium.Translational and Basic Science Research in Early Lesions (TBEL) Program.Small Cell Lung Cancer (SCLC) Consortium.Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). ![]() PREVENT Cancer Preclinical Drug Development Program (PREVENT).Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia).Pancreatic Cancer Detection Consortium (PCDC).NCI Cervical Cancer ‘Last Mile’ Initiative.HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network.Discovery and Development of Natural Products for Cancer Interception and Prevention (DDNP-CIP).Consortium for Imaging and Biomarkers (CIB).Cancer Treatment Tolerability Consortium.Cancer Screening Research Network (CSRN).Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT).Cancer Prevention Clinical Trials Network (CP-CTNet).Cancer Immunoprevention Network (CIP-Net).Barrett's Esophagus Translational Research Network (BETRNet).Alliance of Glycobiologists for Cancer Research.Programs with Webpages within This Site.NCI Community Oncology Research Program (NCORP).Early Detection Research Network (EDRN).Cancer Prevention Fellowship Program (CPFP).
0 Comments
Leave a Reply. |